Monday, April 11, 2022 8:22:57 AM
8:05 am ET April 11, 2022 (PR Newswire) Print
Treatment with HT-KIT prevented cancer cell growth and induced death in neoplastic mast cells over 72 hours
HT-KIT inhibits tumor growth and systemic organ infiltration using both an allograft mastocytosis model and a humanized xenograft MC tumor model.
Orphan Drug status granted, successfully completed API manufacturing feasibility
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced a development updates for its novel cancer therapeutic, HT-KIT.
https://mma.prnewswire.com/media/644804/Hoth_Therapeutics_Logo.jpg
Hoth's innovative approach, which employs a chemically-stable antisense oligonucleotide to target the proto-oncogene KIT through by frameshifting KIT mRNA transcripts, has potential as a KIT-targeted therapeutic alone, or in combination with agents that target KIT signaling, in the treatment of KIT-associated malignancies.
Through a sponsored scientific research agreement with North Carolina State University, the team used the HT-KIT mRNA frame-shifting approach on mast cell leukemia cells in vitro and found that KIT protein expression, signaling and function were reduced. Treatment with HT-KIT prevented cancer cell growth and induced cell death over 72 hours. In a humanized mast cell leukemia mouse model, tumor growth and infiltration of other organs were reduced and tumor cell death increased when HT-KIT induced frameshifted c-KIT mRNA.
Hoth has filed several patent applications to protect this IP throughout the world.
"With our HT-KIT drug, we are flipping off a key cancer signal that's involved in multiple aggressive cancers, such as systemic mastocytosis, mast cell leukemia, gastrointestinal stromal tumors and acute myeloid leukemia. Our approach avoids pitfalls related to KIT mutations by targeting mRNA. Our next round of preclinical studies are underway and we are excited to utilize the results for our planned Pre-IND meeting with FDA later this year," stated Robb Knie, Chief Executive Officer of Hoth.
HT-KIT, a new molecular entity, was designated as an Orphan Drug for the treatment of mastocytosis earlier in 2022. HT-KIT Hoth has successfully completed manufacturing feasibility of the HT-KIT drug substance in collaboration with WuXi STA.
FDA Orphan Drug Designation is granted to investigational therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people in the United States. Orphan drug status provides benefits to drug developers, including assistance in the drug development process, tax credits for clinical costs, exemptions from certain FDA fees and seven years of post-approval marketing exclusivity.
About HT-KIT
HT-KIT is a new molecular entity (NME) under development for treatment of mast cell derived cancers and anaphylaxis. HT-KIT was developed Dr. Glenn Cruse, Assistant Professor at North Carolina State University and shares the same molecular class as Hoth's current HT-004 drug. The HT-KIT drug is designed to more specifically target the receptor tyrosine kinase KIT in mast cells, which is required for the proliferation, survival and differentiation of bone marrow-derived hematopoietic stem cells. Mutations in the KIT pathway have been associated with several human cancers, such as gastrointestinal stromal tumors and mast cell-derived cancers (mast cell leukemia and mast cell sarcoma). Based on the initial proof-of-concept success, Hoth intends to initially target mast cell neoplasms for development of HT-KIT, which is a rare, aggressive cancer with poor prognosis.
About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. Hoth's pipeline development is focused to improve the quality of life for patients suffering from skin toxicities associated with cancer therapy, mast-cell derived cancers and anaphylaxis, Alzheimer's Disease, atopic dermatitis and other indications. To learn more, please visit https://ir.hoththerapeutics.com/.
Forward-Looking Statement
This press release includes forward-looking statements based upon Hoth's current expectations which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates Hoth may develop, and the labeling under any approval Hoth may obtain; the timing and costs of clinical trials, the timing and costs of other expenses; market acceptance of Hoth's products; the ultimate impact of the current Coronavirus pandemic, or any other health epidemic, on Hoth's business, its clinical trials, its research programs, healthcare systems or the global economy as a whole; Hoth's intellectual property; Hoth's reliance on third party organizations; Hoth's competitive position; Hoth's industry environment; Hoth's anticipated financial and operating results, including anticipated sources of revenues; Hoth's assumptions regarding the size of the available market, benefits of Hoth's products, product pricing, timing of product launches; management's expectation with respect to future acquisitions; statements regarding Hoth's goals, intentions, plans and expectations, including the introduction of new products and markets; and Hoth's cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place undue reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms or the negative of those terms. Although Hoth believes that the expectations reflected in the forward-looking statements are reasonable, Hoth cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section entitled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U.S. Securities and Exchange Commission. All such statements speak only as of the date of this press release. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.
Investor Contact:LR Advisors LLCEmail: investorrelations@hoththerapeutics.comwww.hoththerapeutics.comPhone: (678) 570-6791
https://c212.net/c/img/favicon.png?sn=NY20869&sd=2022-04-11
View original content to download multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-mrna-frame-shifting-therapeutic-ht-kit-proves-effective-against-aggressive-cancer-cells-301522484.html
SOURCE Hoth Therapeutics, Inc.
https://rt.prnewswire.com/rt.gif?
New York Yankees and Duke Basketball
Recent HOTH News
- Hoth Therapeutics Announces Promising Preclinical Results for Alzheimer's Drug HT-ALZ • PR Newswire (US) • 09/17/2024 11:57:00 AM
- Hoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a Trial • PR Newswire (US) • 09/05/2024 02:32:00 PM
- Hoth Therapeutics Announces Positive Data from First-of-its-Kind Human Patient Treatment of EGFRI-Associated Skin Toxicities with HT-001 • PR Newswire (US) • 09/05/2024 12:03:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/21/2024 08:15:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/21/2024 08:15:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/21/2024 08:15:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/21/2024 08:15:02 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/16/2024 08:15:32 PM
- Hoth Therapeutics and Aronnax Inc. Enter Master Services Agreement For HT-KIT Cancer Therapeutic • PR Newswire (US) • 08/15/2024 12:04:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 08:05:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2024 08:15:18 PM
- Micro Cap Already Off To The Races At The Bell • AllPennyStocks.com • 07/24/2024 02:30:00 PM
- Hoth Therapeutics Partners with LTS Therapy Systems to Accelerate Novel Alzheimer's Treatment • PR Newswire (US) • 07/24/2024 10:30:00 AM
- Hoth Therapeutics Expands Clinical Trial for Cancer Patients • PR Newswire (US) • 07/16/2024 12:31:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 06/18/2024 10:15:38 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 06/18/2024 10:10:43 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/18/2024 10:07:27 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/17/2024 08:41:10 PM
- Hoth Therapeutics Announces Joint Development Agreement with Wise Systems International SRL to Utilize Artificial Intelligence for Drug Discovery • PR Newswire (US) • 06/10/2024 12:11:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 08:00:56 PM
- Hoth Therapeutics to Attend EF Hutton Annual Global Conference, May 15, 2024 • PR Newswire (US) • 05/01/2024 12:00:00 PM
- Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds • PR Newswire (US) • 03/27/2024 06:00:00 PM
- Hoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for Obesity Treatment • PR Newswire (US) • 03/27/2024 12:27:00 PM
- Hoth Therapeutics Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZ • PR Newswire (US) • 03/19/2024 12:21:00 PM
- Hoth Therapeutics Retains Venable LLP to Expand Its Patent Portfolio • PR Newswire (US) • 02/29/2024 01:38:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM